White E, Bayer T, Kosar C, Santostefano C, Muench U, Oh H
J Am Geriatr Soc. 2024; 73(1):39-49.
PMID: 39434608
PMC: 11735312.
DOI: 10.1111/jgs.19236.
Yashkin A, Kolpakov S, Ukraintseva S, Yashin A, Akushevich I
Clin Diabetes Endocrinol. 2024; 10(1):11.
PMID: 38317215
PMC: 10840251.
DOI: 10.1186/s40842-024-00170-z.
Yashkin A, Kolpakov S, Ukraintseva S, Yashin A, Akushevich I
Res Sq. 2023; .
PMID: 37886578
PMC: 10602068.
DOI: 10.21203/rs.3.rs-2596630/v1.
Ike J, Choi H, Cho T, Howell J, Langa K
Innov Aging. 2023; 7(3):igad015.
PMID: 37033408
PMC: 10079814.
DOI: 10.1093/geroni/igad015.
Lee D, Lee V, Hur S
Front Neurosci. 2022; 16:1042865.
PMID: 36408394
PMC: 9672822.
DOI: 10.3389/fnins.2022.1042865.
Protein and Gene Delivery Systems for Neurodegenerative Disorders: Where Do We Stand Today?.
Siafaka P, Okur M, Erim P, Caglar E, Ozgenc E, Gundogdu E
Pharmaceutics. 2022; 14(11).
PMID: 36365243
PMC: 9698227.
DOI: 10.3390/pharmaceutics14112425.
Availability of New Medicines in the US and Germany From 2004 to 2018.
Blankart K, Naci H, Chandra A
JAMA Netw Open. 2022; 5(8):e2229231.
PMID: 36040738
PMC: 9428736.
DOI: 10.1001/jamanetworkopen.2022.29231.
Expedited regulatory product approval in the time of COVID-19.
Novack G
Ocul Surf. 2022; 26:345-348.
PMID: 35640837
PMC: 9144837.
DOI: 10.1016/j.jtos.2022.05.007.
Survey Results of Speech-Language Pathologists Working With Cognitive-Communication Disorders: Improving Practices for Mild Cognitive Impairment and Early-Stage Dementia From Alzheimer's Disease.
Lanzi A, Saylor A, Cohen M
Am J Speech Lang Pathol. 2022; 31(4):1653-1671.
PMID: 35605597
PMC: 9531927.
DOI: 10.1044/2022_AJSLP-21-00266.
Cost-effectiveness of Aducanumab and Donanemab for Early Alzheimer Disease in the US.
Ross E, Weinberg M, Arnold S
JAMA Neurol. 2022; 79(5):478-487.
PMID: 35344024
PMC: 8961406.
DOI: 10.1001/jamaneurol.2022.0315.
Knowledge and Attitudes Concerning Aducanumab Among Older Americans After FDA Approval for Treatment of Alzheimer Disease.
Zissimopoulos J, Jacobson M, Chen Y, Borson S
JAMA Netw Open. 2022; 5(2):e2148355.
PMID: 35157058
PMC: 8845005.
DOI: 10.1001/jamanetworkopen.2021.48355.
Caring Together: Trajectories of Paid and Family Caregiving Support to Those Living in the Community With Dementia.
Reckrey J, Li L, Zhan S, Wolff J, Yee C, Ornstein K
J Gerontol B Psychol Sci Soc Sci. 2022; 77(Suppl_1):S11-S20.
PMID: 35034123
PMC: 9122661.
DOI: 10.1093/geronb/gbac006.
The value of anticancer drugs - a regulatory view.
Pignatti F, Wilking U, Postmus D, Wilking N, Delgado J, Bergh J
Nat Rev Clin Oncol. 2021; 19(3):207-215.
PMID: 34873312
DOI: 10.1038/s41571-021-00584-z.
The Emerging Role of Metabolism in Brain-Heart Axis: New Challenge for the Therapy and Prevention of Alzheimer Disease. May Thioredoxin Interacting Protein (TXNIP) Play a Role?.
Perrone L, Valente M
Biomolecules. 2021; 11(11).
PMID: 34827650
PMC: 8616009.
DOI: 10.3390/biom11111652.
Aducanumab as a Novel Treatment for Alzheimer's Disease: A Decade of Hope, Controversies, and the Future.
Esang M, Gupta M
Cureus. 2021; 13(8):e17591.
PMID: 34646644
PMC: 8483432.
DOI: 10.7759/cureus.17591.
Instead of wasting money on aducanumab, pay for programs proven to help people living with dementia.
Hunt L, Harrison K, Covinsky K
J Am Geriatr Soc. 2021; 69(12):3690-3692.
PMID: 34480351
PMC: 8648993.
DOI: 10.1111/jgs.17462.